Who
Kevin McCulloch
Officer
Company insider
Files Form 4 as: Officer, Xeris Biopharma Holdings.
In numbers
- Trades disclosed
- 43
- Buys
- 1
- Sells
- 6
- Bought
- $110K
- Sold
- $2.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Aug 2024
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $141K15,000 at $9.41 | filing |
| 28 Sep 2026filed 29 Sep 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $250K25,000 at $10.00 | filing |
| 28 Sep 2026filed 29 Sep 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $250K25,000 at $10.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $127K15,000 at $8.49 | filing |
| 1 Sep 2026filed 1 Sep 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $127K15,000 at $8.49 | filing |
| 3 Aug 2026filed 4 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $120K15,000 at $8.02 | filing |
| 3 Aug 2026filed 4 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $120K15,000 at $8.02 | filing |
| 1 Aug 2026filed 21 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $177K21,918 at $8.08 | filing |
| 1 Aug 2026filed 21 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $177K21,918 at $8.08 | filing |
| 1 Jul 2026filed 2 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $723K90,000 at $8.03 | filing |
| 1 Jul 2026filed 2 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $723K90,000 at $8.03 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $200K48,894 at $4.09 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $164 at $3.94 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | $200K48,894 at $4.09 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | $200K48,894 at $4.09 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | $164 at $3.94 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | $164 at $3.94 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $200K48,894 at $4.09 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $164 at $3.94 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $504K68,454 at $7.36 | filing |
News
Reviewing MediciNova (NASDAQ:MNOV) & Xeris Biopharma (NASDAQ:XERS)XERS · dailypolitical.com · 22 Oct 2026Critical Contrast: Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS)XERS · tickerreport.com · 21 Oct 2026Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)XERS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Kevin McCulloch; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.